Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141


Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.

Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ.

Leukemia. 2019 Oct 18. doi: 10.1038/s41375-019-0602-x. [Epub ahead of print]


Preparation of polymer gold nanoparticle composites with tunable plasmon coupling and their application as SERS substrates.

Belhout SA, Baptista FR, Devereux SJ, Parker AW, Ward AD, Quinn SJ.

Nanoscale. 2019 Nov 14;11(42):19884-19894. doi: 10.1039/c9nr05014k. Epub 2019 Oct 10.


Common bile duct obstruction palliated with common bile duct re-implantation (choledochoduodenostomy) in a cat.

Hayes G, Devereux S, Loftus JP, Jager M, Duhamel G, Stokol T.

Can Vet J. 2019 Oct;60(10):1089-1093.


The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T-cells.

Townsend W, Pasikowska M, Yallop D, Phillips EH, Patten PEM, Salisbury JR, Marcus R, Pepper A, Devereux S.

Haematologica. 2019 Sep 19. pii: haematol.2019.220160. doi: 10.3324/haematol.2019.220160. [Epub ahead of print]


Carbon nanohorn modified platinum electrodes for improved immobilisation of enzyme in the design of glutamate biosensors.

Ford R, Devereux SJ, Quinn SJ, O'Neill RD.

Analyst. 2019 Aug 16;144(17):5299-5307. doi: 10.1039/c9an01085h.


Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.

Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D, Fegan C, McCaig A, Schuh A, Pettitt A, Gribben JG, Patten PEM, Devereux S, Bloor A, Fox CP, Forconi F, Munir T.

J Clin Oncol. 2019 Oct 20;37(30):2722-2729. doi: 10.1200/JCO.19.00894. Epub 2019 Jul 11.


Seasonal Food Insecurity among Farm Workers in the Northern Cape, South Africa.

Devereux S, Tavener-Smith L.

Nutrients. 2019 Jul 5;11(7). pii: E1535. doi: 10.3390/nu11071535.


Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM.

Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.


Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.

Phillips EH, Devereux S, Radford J, Mir N, Adedayo T, Clifton-Hadley L, Johnson R.

Leuk Lymphoma. 2019 Sep;60(9):2291-2294. doi: 10.1080/10428194.2019.1576870. Epub 2019 Feb 18. No abstract available.


Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA.

Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.


Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):803-813.e7. doi: 10.1016/j.clml.2018.08.007. Epub 2018 Aug 18.


Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.

Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre SE, Quach H, Gaidano G, Maslyak Z, Stevens DA, Moreno C, Gill DS, Flinn IW, Gribben JG, Mokatrin A, Cheng M, Styles L, James DF, Kipps TJ, Ghia P.

Am J Hematol. 2018 Nov;93(11):1402-1410. doi: 10.1002/ajh.25259. Epub 2018 Oct 9.


Multimodal Microscopy Distinguishes Extracellular Aggregation and Cellular Uptake of Single-Walled Carbon Nanohorns.

Devereux SJ, Cheung S, Daly HC, O'Shea DF, Quinn SJ.

Chemistry. 2018 Sep 20;24(53):14162-14170. doi: 10.1002/chem.201801532. Epub 2018 Aug 22.


Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells.

Mele S, Devereux S, Pepper AG, Infante E, Ridley AJ.

Blood Adv. 2018 Jul 10;2(13):1551-1561. doi: 10.1182/bloodadvances.2017014506.


Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P.

Haematologica. 2018 Sep;103(9):1502-1510. doi: 10.3324/haematol.2018.192328. Epub 2018 Jun 7.


In vitro and in vivo evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia.

Coulter EM, Pepper A, Mele S, Folarin N, Townsend W, Cuthill K, Phillips EH, Patten PEM, Devereux S.

Haematologica. 2018 Mar;103(3):497-505. doi: 10.3324/haematol.2017.176164. Epub 2017 Dec 14.


Gene therapy for Cystic Fibrosis: Improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways.

Cmielewski P, Farrow N, Devereux S, Parsons D, Donnelley M.

Exp Lung Res. 2017 Nov - Dec;43(9-10):426-433. doi: 10.1080/01902148.2017.1395931. Epub 2017 Dec 13.


Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.

Marsilio S, Khiabanian H, Fabbri G, Vergani S, Scuoppo C, Montserrat E, Shpall EJ, Hadigol M, Marin P, Rai KR, Rabadan R, Devereux S, Pasqualucci L, Chiorazzi N.

Leukemia. 2018 Apr;32(4):1041-1044. doi: 10.1038/leu.2017.343. Epub 2017 Dec 5. No abstract available.


A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation.

Fararjeh FA, Mahmood S, Tachtatzis P, Yallop D, Devereux S, Patten P, Agrawal K, Suddle A, O'Grady J, Heaton N, Marcus R, Kassam S.

Eur J Haematol. 2018 Jan;100(1):98-103. doi: 10.1111/ejh.12988. Epub 2017 Dec 4.


Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids.

Vidler J, Rogers C, Yallop D, Devereux S, Wellving E, Stewart O, Cox A, Hunt KF, Kassam S.

J Clin Transl Endocrinol. 2017 Jun 24;9:18-20. doi: 10.1016/j.jcte.2017.06.003. eCollection 2017 Sep.


Using Mobile Phones to Improve Vaccination Uptake in 21 Low- and Middle-Income Countries: Systematic Review.

Oliver-Williams C, Brown E, Devereux S, Fairhead C, Holeman I.

JMIR Mhealth Uhealth. 2017 Oct 4;5(10):e148. doi: 10.2196/mhealth.7792.


A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Pratt G, Yap C, Oldreive C, Slade D, Bishop R, Griffiths M, Dyer MJS, Fegan C, Oscier D, Pettitt A, Matutes E, Devereux S, Allsup D, Bloor A, Hillmen P, Follows G, Rule S, Moss P, Stankovic T.

Br J Haematol. 2018 Aug;182(3):429-433. doi: 10.1111/bjh.14793. Epub 2017 Jun 23. No abstract available.


The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma.

Davies JM, Osborne TR, Edmonds PM, Schey SA, Devereux S, Higginson IJ, Ramsenthaler C.

Eur J Haematol. 2017 May;98(5):508-516. doi: 10.1111/ejh.12864. Epub 2017 Mar 9.


Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.

Dhanapal V, Gunasekara M, Lianwea C, Marcus R, De Lord C, Bowcock S, Devereux S, Patten P, Yallop D, Wrench D, Fields P, Kassam S.

Leuk Lymphoma. 2017 Sep;58(9):1-9. doi: 10.1080/10428194.2016.1276288. Epub 2017 Jan 16.


NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.

Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S, Follows G, Fox CP, Gribben J, Hillmen P, Hatton CS, Littlewood TJ, McCarthy H, Murray J, Pettitt AR, Soilleux E, Stamatopoulos B, Love SB, Wotherspoon A, Schuh A.

Br J Haematol. 2016 Oct;175(1):43-54. doi: 10.1111/bjh.14177. Epub 2016 Jul 5.


Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration.

Pasikowska M, Walsby E, Apollonio B, Cuthill K, Phillips E, Coulter E, Longhi MS, Ma Y, Yallop D, Barber LD, Patten P, Fegan C, Ramsay AG, Pepper C, Devereux S, Buggins AG.

Blood. 2016 Jul 28;128(4):563-73. doi: 10.1182/blood-2016-01-683128. Epub 2016 Jun 1.


ALK-positive large B-cell lymphoma with strong CD30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib.

Mehra V, Pomplum S, Ireland R, Yallop D, Devereux S, Marcus R, Shah C, Patten P, Kassam S.

Histopathology. 2016 Nov;69(5):880-882. doi: 10.1111/his.13002. Epub 2016 Jul 19. No abstract available.


Long-Lived Excited-State Dynamics of i-Motif Structures Probed by Time-Resolved Infrared Spectroscopy.

Keane PM, Baptista FR, Gurung SP, Devereux SJ, Sazanovich IV, Towrie M, Brazier JA, Cardin CJ, Kelly JM, Quinn SJ.

Chemphyschem. 2016 May 4;17(9):1281-7. doi: 10.1002/cphc.201501183. Epub 2016 Feb 17.


Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR.

N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.


Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators.

N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.


Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism.

Bürgler S, Gimeno A, Parente-Ribes A, Wang D, Os A, Devereux S, Jebsen P, Bogen B, Tjønnfjord GE, Munthe LA.

J Immunol. 2015 Jan 15;194(2):827-35. doi: 10.4049/jimmunol.1401350. Epub 2014 Dec 10.


Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.

Pepper C, Buggins AG, Jones CH, Walsby EJ, Forconi F, Pratt G, Devereux S, Stevenson FK, Fegan C.

Leukemia. 2015 Mar;29(3):744-7. doi: 10.1038/leu.2014.308. Epub 2014 Oct 28. No abstract available.


Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital.

Wang M, Wang W, Abeywardane A, Adikarama M, McLornan D, Raj K, de Lavallade H, Devereux S, Mufti GJ, Pagliuca A, Potter VT, Mijovic A.

Biol Blood Marrow Transplant. 2015 Jan;21(1):60-6. doi: 10.1016/j.bbmt.2014.09.009. Epub 2014 Sep 28.


Study of picosecond processes of an intercalated dipyridophenazine Cr(III) complex bound to defined sequence DNAs using transient absorption and time-resolved infrared methods.

Devereux SJ, Keane PM, Vasudevan S, Sazanovich IV, Towrie M, Cao Q, Sun XZ, George MW, Cardin CJ, Kane-Maguire NA, Kelly JM, Quinn SJ.

Dalton Trans. 2014 Dec 21;43(47):17606-9. doi: 10.1039/c4dt01989j.


Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.


Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma.

Noriega V, Kaur H, Devereux S, Byrne J, Marcus R, Haynes A, Yallop D, McMillan A, Ingram W, Khan A, Kenyon M, Potter V, Russell N, Mufti GJ, Pagliuca A.

Leuk Res. 2014 Jul;38(7):737-43. doi: 10.1016/j.leukres.2014.03.005. Epub 2014 Mar 18.


Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia.

Walsby E, Buggins A, Devereux S, Jones C, Pratt G, Brennan P, Fegan C, Pepper C.

Blood. 2014 Jun 5;123(23):3607-17. doi: 10.1182/blood-2013-12-544569. Epub 2014 Mar 17.


Analysis of a potential cluster of rhinovirus infections in patients and staff on two haemato-oncology wards.

Cutino-Moguel T, Lauinger IL, Srivastava S, Zuckerman M, Tong CY, Devereux S.

J Clin Virol. 2014 May;60(1):57-9. doi: 10.1016/j.jcv.2014.02.003. Epub 2014 Feb 17.


Rho and Rap guanosine triphosphatase signaling in B cells and chronic lymphocytic leukemia.

Mele S, Devereux S, Ridley AJ.

Leuk Lymphoma. 2014 Sep;55(9):1993-2001. doi: 10.3109/10428194.2013.866666. Epub 2013 Dec 31. Review.


Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome.

Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, de Lavallade H, Dhouri A, Marsh JC, Marcus R, Devereux S, Ho A, Pagliuca A, Mufti GJ.

Biol Blood Marrow Transplant. 2014 Jan;20(1):111-7. doi: 10.1016/j.bbmt.2013.10.021. Epub 2013 Nov 8.


How I treat patients with relapsed chronic lymphocytic leukaemia.

Cuthill K, Devereux S.

Br J Haematol. 2013 Nov;163(4):423-35. doi: 10.1111/bjh.12549. Epub 2013 Sep 2.


Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma.

Møller H, Purushotham A, Linklater KM, Garmo H, Holmberg L, Lambe M, Yallop D, Devereux S.

Eur J Cancer. 2013 Nov;49(17):3686-93. doi: 10.1016/j.ejca.2013.06.047. Epub 2013 Aug 6.


Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.

Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM, de Lavallade H, Kenyon M, Ireland RM, Marsh JC, Devereux S, Pagliuca A, Mufti GJ.

Biol Blood Marrow Transplant. 2013 Apr;19(4):562-8. doi: 10.1016/j.bbmt.2012.12.013. Epub 2012 Dec 21.


Lymphadenopathy and splenomegaly in an HIV-infected man.

Winchester SA, Tedder RS, Pomplun S, Sudhanva M, Zuckerman M, Poulton M, Devereux S, Schey S.

J Clin Virol. 2013 Mar;56(3):181-4. doi: 10.1016/j.jcv.2012.08.004. Epub 2012 Aug 29. No abstract available.


Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells.

Hamilton E, Pearce L, Morgan L, Robinson S, Ware V, Brennan P, Thomas NS, Yallop D, Devereux S, Fegan C, Buggins AG, Pepper C.

Br J Haematol. 2012 Sep;158(5):589-99. doi: 10.1111/j.1365-2141.2012.09191.x. Epub 2012 Jun 19.


Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P.

J Clin Oncol. 2012 May 10;30(14):1647-55. doi: 10.1200/JCO.2011.35.9695. Epub 2012 Apr 9.


Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).

Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S, Ho A, Devereux S, Mufti GJ, Pagliuca A.

Leuk Res. 2012 Jul;36(7):857-61. doi: 10.1016/j.leukres.2011.12.004. Epub 2011 Dec 29.


Primary effusion lymphoma in an HIV-negative man.

Gandhi SA, Mufti G, Devereux S, Ireland R.

Br J Haematol. 2011 Nov;155(4):411. doi: 10.1111/j.1365-2141.2011.08778.x. Epub 2011 Jul 18. No abstract available.


Two-faced T cells in CLL.

Devereux S.

Blood. 2011 May 19;117(20):5273-4. doi: 10.1182/blood-2011-03-342709.


Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.

Ramasamy K, Mahmood S, Lim Z, Corderoy S, Devereux S, Mufti GJ, Pagliuca A, Schey S.

Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):242-5. doi: 10.1016/j.clml.2011.03.004. Epub 2011 Apr 8.


Supplemental Content

Loading ...
Support Center